Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AVAX Technologies
ClinicalTrials.gov Identifier:
NCT00257465
First received: November 22, 2005
Last updated: July 10, 2013
Last verified: July 2013
  Purpose

The purpose of this study is to determine whether a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and stimulates an immune response to patients' own cancer cells.


Condition Intervention Phase
Melanoma
Biological: Autologous, DNP-modified vaccine (M-Vax)
Biological: Autologous, DNP-Modified Melanoma Vaccine
Biological: Autologous, DNP-Modified Vaccine
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma

Resource links provided by NLM:


Further study details as provided by AVAX Technologies:

Primary Outcome Measures:
  • Immune response to patients' own melanoma cells [ Time Frame: 2 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]

Enrollment: 82
Study Start Date: June 2005
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
'Autologous, DNP-modified vaccine (M-Vax)'
Biological: Autologous, DNP-modified vaccine (M-Vax)
5.0, 2.5, 0.5, or 0 cells
Biological: Autologous, DNP-Modified Melanoma Vaccine
5 million cells
Other Name: MVax
Experimental: B
Autologous, DNP-Modified Vaccine (MVax)
Biological: Autologous, DNP-modified vaccine (M-Vax)
5.0, 2.5, 0.5, or 0 cells
Biological: Autologous, DNP-Modified Vaccine
2.5 million cells
Other Name: MVax
Experimental: C
Autologous, DNP-Modified Vaccine (MVax)
Biological: Autologous, DNP-modified vaccine (M-Vax)
5.0, 2.5, 0.5, or 0 cells
Biological: Autologous, DNP-Modified Vaccine
0.5 million cells
Other Name: MVax
Placebo Comparator: D
0 cells
Biological: Autologous, DNP-Modified Vaccine
0 cells
Other Name: MVax

Detailed Description:

Patients with stage III or IV melanoma need to have at least one tumor mass of at least 2.5 cm (about 1 inch) diameter than can be removed for vaccine production. If the vaccine is successfully made and if the patient is eligible, the patient will be assigned to receive one of 4 doses of the vaccine, include one group that will receive a zero dose. All patients will receive injections of their vaccine as part of immune system testing and will receive low dose cyclophosphamide and BCG. Eight injections of the vaccine will be administered as an injection into the skin of the arm over a 6 month period. Before and after vaccine administration, patients will be tested for immunity to their own melanoma cells by DTH testing, which is similar to a tuberculosis test. All side effects caused by the vaccine will be recorded.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • stage III or IV melanoma at least one tumor mass of at least 2.5 cm diameter that can be excised to make vaccine good performance status

Exclusion Criteria:

  • brain metastases need for steroids or other immunosuppressive drugs positive PPD tests positive test for HIV, hepatitis B (antigen), or hepatitis C other serious medical illnesses
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00257465

Locations
United States, Arizona
University of Arizona Cancer Center
Tucson, Arizona, United States
United States, California
Pacific Oncology and Hematology Associates
San Diego, California, United States, 92024
United States, Illinois
University of Illinois School of Medicine
Chicago, Illinois, United States, 60612
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States
United States, Pennsylvania
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
AVAX Technologies
Investigators
Principal Investigator: David Berd, MD AVAX Technologies
  More Information

Publications:
Responsible Party: AVAX Technologies
ClinicalTrials.gov Identifier: NCT00257465     History of Changes
Other Study ID Numbers: A/100/0401
Study First Received: November 22, 2005
Last Updated: July 10, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by AVAX Technologies:
melanoma
metastatic
vaccine
immunotherapy
autologous

Additional relevant MeSH terms:
Melanoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas

ClinicalTrials.gov processed this record on November 27, 2014